ArticleFrontiers in nephrology2026
The lactate dehydrogenase-to-albumin ratio is independently associated with moderate-to-severe tubulointerstitial fibrosis in patients with IgA nephropathy.
Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tubulointerstitial fibrosis accelerates the progression of immunoglobulin A nephropathy (IgAN) to end-stage renal disease (ESRD). While renal biopsy is the standard for evaluation, non-invasive biomarkers remain scarce. This study investigated the independent association and diagnostic value of the lactate dehydrogenase-to-albumin ratio (LAR) for moderate-to-severe tubulointerstitial fibrosis (Oxford T1+T2) in IgAN patients. Methods: We retrospectively analyzed 398 patients with biopsy-proven primary IgAN, categorized into no/mild fibrosis (T0, n=273) and moderate-to-severe fibrosis (T1+T2, n=125) groups. Clinical, laboratory, and pathological data were collected to calculate LAR. Missing data were handled using multiple imputation by chained equations (MICE). Statistical evaluations included logistic regression, ROC curves, restricted cubic splines (RCS), and subgroup analyses. Results: The T1+T2 group exhibited significantly higher median LAR levels (5.10 vs. 4.13, P < 0.001). Following adjustment for confounders, LAR remained independently associated with fibrosis (OR = 1.425, 95% CI: 1.122-1.809, P = 0.004). The AUC was 0.717, with an optimal cut-off of 4.91 (sensitivity 56.8%, specificity 78.0%). RCS analysis indicated a linear relationship (P for non-linearity = 0.2350). Subgroup analyses showed consistent positive associations (OR > 1.2), reaching statistical significance in males, patients aged ≥40 years, and those with eGFR ≥60 mL/min/1.73 m². Sensitivity analyses confirmed robustness. Patients with LAR > 4.91 demonstrated worse renal function, heavier proteinuria, and higher fibrosis incidence (54.2% vs. 20.2%, P < 0.001). Conclusion: LAR is independently associated with moderate-to-severe tubulointerstitial fibrosis and demonstrates moderate diagnostic efficacy. As a cost-effective indicator, LAR may serve as a non-invasive auxiliary tool for clinical screening and risk stratification in IgAN, but it cannot replace renal biopsy as the diagnostic gold standard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.